NCT05384119
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy), Tyrosine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be currently receiving Ibrance/palbociclib and aromatase inhibitor (AI) therapy (e.g. Arimidex/anastrozole, Aromasin/exemestane, Femara/letrozole) in the metastatic setting with evidence of progressive disease – see trial for details
Exclusions: Patients with more than 1 prior line of systemic treatment (Ibrance/palbociclib & AI) in the locally advanced or metastatic setting; Patients with prior exposure to any STAT3 inhibitor; Patients with known loss of retinoblastoma tumor suppressor gene (Rb) or estrogen receptor 1 (ESR1) activating mutation
https://ClinicalTrials.gov/show/NCT05384119